FDA Brief

Warning letters Food

FDA warning letter to

American Global Health Group, LLC

LowIssued Jan 22, 2021Posted Feb 2, 2021Division of Human and Animal Food Operations West VI

FDA warned American Global Health Group that AloeCure website and Facebook claims make its products unapproved new drugs and misbranded.

What happened

FDA reviewed www.aloecure.com in December 2020 and January 2021 and the AloeCure Facebook page, which directs users to the website for purchase. FDA found claims and testimonials that the AloeCure products treat, cure, mitigate, or prevent diseases such as acid reflux, heartburn, joint pain, arthritis, and enzyme deficiencies. FDA concluded the products are unapproved new drugs and that two products are misbranded for lacking adequate directions for use.

What FDA found

  1. FDA says the website and Facebook claims show the products are intended to cure, mitigate, treat, or prevent disease, so they are drugs.

    section 201(g)(1)(B) of the Act [21 U.S.C. § 321(g)(1)(B)]
  2. FDA says the products are new drugs because they are not generally recognized as safe and effective for those uses and lack FDA approval.

    sections 201(p), 301(d), and 505(a) of the Act [21 U.S.C. § 321(p), § 331(d), § 355(a)]
  3. FDA says AloeCure Probiotic & Enzyme Blend and AloeCure VeraFlex are misbranded because they lack adequate directions for use for diseases that a layperson cannot safely self-diagnose or treat.

    section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]; 21 CFR 201.5
  4. FDA says selling these misbranded drugs in interstate commerce violates the Act.

    section 301(a) of the Act [21 U.S.C. § 331(a)]

What FDA wants

FDA asks the company to notify it in writing within 15 working days of receipt of the specific steps taken to correct the violations and prevent recurrence, with supporting documents; if correction is not complete, the company must explain the delay and state when it will be complete.

Who should pay attention

  • dietary supplement brands that make disease claims on websites or social media
  • aloe and probiotic product sellers using testimonials
  • regulatory and marketing teams reviewing online product claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk